Table 1. Patient demographics.
| Characteristic | Endometrial cancer cohort | Epithelial ovarian cancer cohort | ||
|---|---|---|---|---|
| Synchronous ovarian cancer (+) | Synchronous ovarian cancer (-) | Synchronous endometrial cancer (+) | Synchronous endometrial cancer (-) | |
| Number | 4,082 (1.7%) | 231,372 (98.3%) | 3,940 (3.6%) | 106,123 (96.4%) |
| Age (y) | 56.1 (±12.6) | 63.5 (±12.4) | 55.6 (±12.2) | 62.3 (±14.3) |
| ≥60 | 1,484 (1.0%) | 143,673 (99.0%) | 1,360 (2.2%) | 61,744 (97.8%) |
| 50-59 | 1,255 (2.1%)* | 59,925 (97.9%) | 1,256 (4.9%)* | 24,196 (95.1%) |
| 40-49 | 1,010 (4.7%)* | 20,667 (95.3%) | 1,028 (6.9%)* | 13,965 (93.1%) |
| < 40 | 333 (4.5%)* | 7,107 (95.5%) | 296 (4.5%) | 6,218 (95.5%) |
| Ethnicity | ||||
| White | 3,267 (1.8%) | 180,070 (98.2%) | 3,156 (3.7%) | 83,026 (96.3%) |
| Black | 162 (0.9%)* | 17,201 (99.1%) | 158 (2.2%)* | 7,066 (97.8%) |
| Hispanic | 321 (1.8%) | 17,693 (98.2%) | 289 (3.3%)* | 8,588 (96.7%) |
| Asian | 261 (2.1%)* | 11,958 (97.9%) | 265 (4.2%)* | 5,995 (95.8%) |
| Others | 71 (1.6%)* | 4,450 (98.4%) | 72 (4.7%) | 1,448 (95.3%) |
| Marital status | ||||
| Single | 965 (2.8%) | 32,939 (97.2%) | 961 (6.0%) | 15,011 (94.0%) |
| Married | 2,113 (1.7%)* | 119,461 (98.3%) | 2,078 (3.6%)* | 54,915 (96.4%) |
| Others | 1,004 (1.3%)* | 78,892 (98.7%) | 901 (2.4%)* | 36,197 (97.6%) |
| Registry Area | ||||
| West | 2,035 (1.7%) | 118,951 (98.3%) | 1,997 (3.5%) | 55,049 (96.5%) |
| Central | 929 (1.7%) | 54,469 (98.3%) | 886 (3.4%) | 24,800 (96.5%) |
| East | 1,118 (1.9%) | 57,952 (98.1%) | 1,057 (3.9%)* | 26,274 (96.1%) |
| Year at diagnosis | ||||
| 1973-1979 | 264 (1.3%) | 20,607 (98.7%) | 250 (2.9%) | 8,488 (97.1%) |
| 1980-1989 | 505 (1.8%)* | 26,994 (98.2%) | 475 (3.2%) | 14,227 (96.8%) |
| 1990-1999 | 692 (1.7%)* | 38,875 (98.3%) | 681 (3.3%)* | 19,949 (96.7%) |
| 2000-2009 | 1,835 (1.9%)* | 96,275 (98.1%) | 1,764 (3.8%) | 45,258 (96.2%) |
| 2010-2013 | 786 (1.6%)* | 48,621 (98.4%) | 770 (4.1%) | 18,201 (95.5%) |
| Stage | ||||
| I | 2,751 (1.8%) | 147,820 (98.2%) | 1,972 (8.5%) | 21,201 (91.5%) |
| II | 220 (2.2%)* | 9,900 (97.8%) | 547 (6.6%) | 7,707 (93.4%) |
| III | 329 (1.6%) | 19,839 (98.4%) | 878 (2.4%)* | 35,963 (97.6%) |
| IV | 242 (1.4%) | 16,692 (98.6%) | 424 (1.2%)* | 35,310 (98.8%) |
| Unknown | 540 (1.4%)* | 37,121 (98.6%) | 119 (2.0%)* | 5,942 (98.0%) |
| Histology | ||||
| Endometrioid | 3,185 (1.8%) | 174,711 (98.2%) | 2,069 (16.4%) | 10,560 (83.6%) |
| Serous | 281 (1.9%)* | 14,144 (98.1%) | 816 (1.5%)* | 55,179 (98.5%) |
| Clear | 32 (1.1%) | 3,003 (98.9%) | 148 (2.7%)* | 5,392 (97.3%) |
| Others | 584 (1.5%) | 39,514 (98.5%) | 907 (2.5%)* | 34,992 (97.5%) |
| Grade | ||||
| 1 | 1,535 (1.8%) | 83,031 (98.2%) | 950 (10.8%) | 7,868 (89.2%) |
| 2 | 1,183 (1.9%)* | 61,203 (98.1%) | 1,160 (7.0%)* | 15,508 (93.0%) |
| 3 | 631 (1.3%) | 48,961 (98.7%) | 913 (1.9%)* | 45,913 (98.1%) |
| Unknown | 733 (1.9%)* | 38,177 (98.1%) | 917 (2.4%)* | 36,834 (97.6%) |
| Tumor size (cm) | ||||
| < 2.0 (or 10†) | 451 (2.1%) | 21,549 (98.0%) | 1,383 (4.1%) | 32,098 (95.9%) |
| ≥ 2.0 (or 10†) | 1,162 (1.5%)* | 78,699 (98.5%) | 948 (5.0%)* | 18,179 (95.0%) |
| Unknown | 2,469 (1.8%) | 134,124 (98.2%) | 1,609 (2.8%)* | 55,846 (97.2%) |
Number (%) per row or mean (±standard deviation) is shown (per column is shown in Supplementary Table 5). All covariates were statistically significant in chi-square test on univariable analysis. *P < 0.05 on multivariable analysis with binary logistic regression models (entered all the listed covariates; the top item in each covariate served as the reference). †size cutoff for the epithelial ovarian cancer cohort.